Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365612 · ClinicalTrials.gov registry record · Phase 4
Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients
A Phase 4 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 300
- Enrollment target
NCT00365612 is a Phase 4 study that has completed, run by Gilead Sciences. The registered enrollment target is 300 participants.
The verdict
NCT00365612, a Phase 4 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 300 participants
- Enrollment target
Study Summary
To compare the effectiveness (efficacy, safety \& tolerability) of a Single Tablet Regimen of efavirenz/emtricitabine/tenofovir DF to subjects continuing on unmodified HAART as measured by the proportion of patients who maintain viral load (HIV-1 RNA) \<200 copies/mL at Week 48.
Interventions
- DRUG Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-07 |
| Est. Completion | 2008-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00365612
The ClinicalTrials.gov registry entry for NCT00365612 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF) is the first listed.
NCT00365612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00365612 about?
NCT00365612 is a clinical study titled "Single Tablet Regimen (STR) Simplification Study for HIV-1 Infected Patients". To compare the effectiveness (efficacy, safety \& tolerability) of a Single Tablet Regimen of efavirenz/emtricitabine/tenofovir DF to subjects continuing on unmodified HAART as measured by the proportion of patients who maintain viral load (HIV-1 RNA) \<200 copies/mL at Week 48.
What is the current status of trial NCT00365612?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 300 participants. The study started on 2006-07. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00365612?
The interventions under investigation include: Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF) (DRUG).
Who is sponsoring clinical trial NCT00365612?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.